KYNTRA BIO, INC. 8-K

What Happened

• Kyntra Bio, Inc. announced financial results for the quarter ended March 31, 2026 in a press release issued May 11, 2026. The company furnished that press release as Exhibit 99.1 to an 8-K under Item 2.02 (Results of Operations and Financial Condition). The filing was signed by David DeLucia, Senior Vice President and Chief Financial Officer.

Key Details

• Filing date: May 11, 2026 (8-K submitted and press release furnished).
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Exhibit included: Press Release (Exhibit 99.1) announcing the quarterly results.
• Signatory: David DeLucia, SVP & CFO, signed the report on behalf of the company.

Why It Matters

• This 8-K is the company’s public disclosure that its quarterly earnings and financial condition information were released; investors should review the furnished press release for revenue, earnings, guidance, and other material metrics.
• Quarterly results can affect Kyntra Bio’s stock performance and investor decisions, so timely access to the press release lets retail investors assess recent operational and financial trends.
• Because the details are provided via the press release exhibit, check the Exhibit 99.1 text and the company’s subsequent filings for full financial statements, management commentary, and any forward-looking information.